EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression

Lu Ding, Reyizha Nuersulitan, Jingjing Wang, Hanxiao Chen, Minglei Zhuo iD

Current Oncology · 2026

DOI: 10.3390/curroncol33050258 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Current Oncology, 2026. Verfasst von Lu Ding und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department I of Thoracic Oncology, Peking University Cancer Hosp…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, B7-H1 Antigen, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Natural Science Foundation, Beijing Research Ward Excellence Program BRWEP2024W032150100, WU JIEPING MEDICAL FOUNDATION.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anaplastic lymphoma kinase (ALK) rearrangement is a well-established oncogenic driver alteration in non-small cell lung cancer (NSCLC), and ALK tyrosine kinase inhibitors (TKIs), particularly lorlatinib, have significantly improved the prognosis of ALK-positive NSCLC patients. Although high programmed death-ligand 1 (PD-L1) expression (≥50%) is generally associated with favorable responses to immune checkpoint inhibitors (ICIs), PD-L1 has not been shown to reliably predict ICI benefit in ALK-rearranged disease, and optimal management after ALK TKI resistance remains challenging. Herein, we report a case of an elderly patient with ALK-rearrangement and exceptionally high PD-L1 expression (TPS ≥ 95%) NSCLC who experienced disease progression following first-line lorlatinib with genetically confirmed MET amplification. The patient subsequently received an exploratory combination of continued lorlatinib plus envafolimab and achieved partial response (PR) with manageable tolerability after 4 months, highlighting a potential sequential strategy that may warrant further investigation in select ALK-positive NSCLC patients exhibiting both bypass pathway activation and exceptionally high PD-L1 expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmLung NeoplasmsHumansMaleAminopyridinesAnaplastic Lymphoma KinaseAntibodies, Monoclonal, HumanizedLactamsLactams, MacrocyclicProtein Kinase InhibitorsPyrazoles

Stichwörter der Autor:innen

ALK-positive non-small cell lung cancerTKI resistancecase reportenvafolimabhigh PD-L1 expressionlorlatinib

Substanzen

ALK protein, humanAminopyridinesAnaplastic Lymphoma KinaseAntibodies, Monoclonal, HumanizedB7-H1 AntigenCD274 protein, humanLactamsLactams, MacrocycliclorlatinibProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department I of Thoracic Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.

ORCID-Profile: Minglei Zhuo

Förderung

  • Beijing Natural Science Foundation
  • Beijing Research Ward Excellence Program BRWEP2024W032150100
  • WU JIEPING MEDICAL FOUNDATION
  • Clinical Research Fund for Distinguished Young Scholars of Peking University Cancer Hospital
  • Guangzhou Life oasis public service center Research and exchange program in the field of health
  • Beijing Xisike Clinical Oncology Research Foundation
  • Beijing Vlove Charity Foundation

Zitieren

APA

Ding, L., Nuersulitan, R., Wang, J., Chen, H., & Zhuo, M. (2026). Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression. Current Oncology. https://doi.org/10.3390/curroncol33050258

Vancouver

Ding L, Nuersulitan R, Wang J, Chen H, Zhuo M. Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression. Current Oncology. 2026. doi:10.3390/curroncol33050258

BibTeX
@article{Ding2026,
  author = {Ding, Lu and Nuersulitan, Reyizha and Wang, Jingjing and Chen, Hanxiao and Zhuo, Minglei},
  title = {Overcoming Acquired MET-Driven Resistance to First-Line Lorlatinib: Successful Combination of Lorlatinib and Envafolimab in an ALK-Positive NSCLC Patient with Ultra-High PD-L1 Expression},
  journal = {Current Oncology},
  year = {2026},
  doi = {10.3390/curroncol33050258}
}
Kostenlos starten →